@marshalj23.bsky.social
Reposted
Read Abraham’s full essay on her diagnosis and journey with colon cancer with interviews from other survivors, advocates, and clinicians, including Dr. John Marshall.
New York Magazine
Colorectal cancer is the second-most-common cause of cancer fatalities in the United States, with 150,000 diagnoses annually and 52,000 deaths; only lung cancer kills more. It has grabbed headlines...
www.facebook.com
August 28, 2025 at 2:57 AM
Read Abraham’s full essay on her diagnosis and journey with colon cancer with interviews from other survivors, advocates, and clinicians, including Dr. John Marshall.
Reposted
"Badge-up" with @marshalj23.bsky.social of @georgetownlombardi.bsky.social as he discusses #ASCO25 with @clinicalcaresol.bsky.social. Watch now: clinicalcaresolutions.net/activities/o...
June 12, 2025 at 8:40 PM
"Badge-up" with @marshalj23.bsky.social of @georgetownlombardi.bsky.social as he discusses #ASCO25 with @clinicalcaresol.bsky.social. Watch now: clinicalcaresolutions.net/activities/o...
Reposted
After #ASCO25, stay up-to-date on the latest GI Cancer Research. View this week's tailored GI Cancer publication output via bit.ly/454GquF and sign up to have this weekly list delivered to your inbox: bit.ly/RueschWeeklyPub.
June 2, 2025 at 11:33 PM
After #ASCO25, stay up-to-date on the latest GI Cancer Research. View this week's tailored GI Cancer publication output via bit.ly/454GquF and sign up to have this weekly list delivered to your inbox: bit.ly/RueschWeeklyPub.
Reposted
In this week's Ruesch Center GI Cancers publication search, @marshalj23.bsky.social highlighted research by Julien Taieb, Pierre Laurent-Puig, and others published in the Journal of Clinical Oncology. bit.ly/3Fkx2bI. Learn more: youtu.be/JlqL1f6vyak?...
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer.
YouTube video by The Ruesch Center
youtu.be
May 15, 2025 at 10:46 PM
In this week's Ruesch Center GI Cancers publication search, @marshalj23.bsky.social highlighted research by Julien Taieb, Pierre Laurent-Puig, and others published in the Journal of Clinical Oncology. bit.ly/3Fkx2bI. Learn more: youtu.be/JlqL1f6vyak?...
Reposted
View this week's tailored GI Cancer publication output via bit.ly/431rg6J. Sign up today to have this weekly list delivered to your inbox: bit.ly/RueschWeeklyPub. What research excited you this week?
May 8, 2025 at 10:03 PM
View this week's tailored GI Cancer publication output via bit.ly/431rg6J. Sign up today to have this weekly list delivered to your inbox: bit.ly/RueschWeeklyPub. What research excited you this week?
Reposted
This week, we highlighted research by Jill P Smith, Narayan Shivapurkar, Wenqiang Chen, Godhanjali Chekuri, Amani Dabney, Kyle Holmes, Hong Cao, Ruvanthi N Kularatne, and Stephan T Stern published in the Journal of Molecular Cancer Therapeutics. Learn more: bit.ly/4lTknwY
April 30, 2025 at 10:26 PM
This week, we highlighted research by Jill P Smith, Narayan Shivapurkar, Wenqiang Chen, Godhanjali Chekuri, Amani Dabney, Kyle Holmes, Hong Cao, Ruvanthi N Kularatne, and Stephan T Stern published in the Journal of Molecular Cancer Therapeutics. Learn more: bit.ly/4lTknwY
Reposted
Save the Date for the 16th Annual Ruesch Center Symposium- Nov 21-22, 2025! @georgetownlombardi.bsky.social @marshalj23.bsky.social @onclive.bsky.social @medstarhealth.bsky.social
April 30, 2025 at 5:48 PM
Save the Date for the 16th Annual Ruesch Center Symposium- Nov 21-22, 2025! @georgetownlombardi.bsky.social @marshalj23.bsky.social @onclive.bsky.social @medstarhealth.bsky.social
Reposted
In an interview with Peers & Perspectives in Oncology, Dr. John Marshall discussed treatment approaches and sequencing for refractory colorectal cancer.
www.targetedonc.com/view/managin...
www.targetedonc.com/view/managin...
Managing Colorectal Cancer Requires Using All Available Options
In an interview with Peers & Perspectives in Oncology, John L. Marshall, MD, discussed treatment approaches and sequencing for refractory colorectal cancer.
www.targetedonc.com
April 23, 2025 at 5:22 PM
In an interview with Peers & Perspectives in Oncology, Dr. John Marshall discussed treatment approaches and sequencing for refractory colorectal cancer.
www.targetedonc.com/view/managin...
www.targetedonc.com/view/managin...
Reposted
Pancreatic Cancer 2025: After More Than 30 Years, Is That Light on the Horizon? @marshalj23.bsky.social shares insights in the Spring Issue of Oncolytics Today. Read the full article, pages 77-79-https://www.ncoda.org/news/oncolytics-today-spring-2025/
April 23, 2025 at 5:59 PM
Pancreatic Cancer 2025: After More Than 30 Years, Is That Light on the Horizon? @marshalj23.bsky.social shares insights in the Spring Issue of Oncolytics Today. Read the full article, pages 77-79-https://www.ncoda.org/news/oncolytics-today-spring-2025/
Reposted
This week, we highlighted exciting research by Berend J van der Wilk, Ben M Eyck, Bas P L Wijnhoven, Sjoerd M Lagarde, J Jan B van Lanschot, and others published in @thelancetoncol.bsky.social. Learn more: bit.ly/3GkX52V.
April 22, 2025 at 11:40 PM
This week, we highlighted exciting research by Berend J van der Wilk, Ben M Eyck, Bas P L Wijnhoven, Sjoerd M Lagarde, J Jan B van Lanschot, and others published in @thelancetoncol.bsky.social. Learn more: bit.ly/3GkX52V.
Reposted
@marshalj23.bsky.social and @marklewismd.bsky.social discuss how ctDNA clearance rates during and after adjuvant chemotherapy (ACT) in the BESPOKE trial provide critical insights into treatment efficacy and may serve as an early predictor of long-term patient outcomes. bit.ly/4luOsmd
BESPOKE: ctDNA Clearance During and After ACT
Panelists discuss how circulating tumor DNA (ctDNA) clearance rates during and after adjuvant chemotherapy (ACT) in the BESPOKE trial provide critical insights into treatment efficacy and may serve as...
www.cancernetwork.com
April 14, 2025 at 4:47 PM
@marshalj23.bsky.social and @marklewismd.bsky.social discuss how ctDNA clearance rates during and after adjuvant chemotherapy (ACT) in the BESPOKE trial provide critical insights into treatment efficacy and may serve as an early predictor of long-term patient outcomes. bit.ly/4luOsmd
Reposted
Mass layoffs. Funding cuts. Uncertain futures.
@marshalj23.bsky.social unpacks the turmoil hitting federal health agencies and what it means for researchers, clinical trials, and patient care. Who benefits from this chaos, and how can the medical community push back?
bit.ly/42nXXLw
@marshalj23.bsky.social unpacks the turmoil hitting federal health agencies and what it means for researchers, clinical trials, and patient care. Who benefits from this chaos, and how can the medical community push back?
bit.ly/42nXXLw
Episode 13 | CCS
As a nationally recognized provider of continuing education for healthcare professionals, CCS develops, delivers, and evaluates a broad range of accredited, cutting-edge CME and CE opportunities.
clinicalcaresolutions.net
April 8, 2025 at 10:02 PM
Mass layoffs. Funding cuts. Uncertain futures.
@marshalj23.bsky.social unpacks the turmoil hitting federal health agencies and what it means for researchers, clinical trials, and patient care. Who benefits from this chaos, and how can the medical community push back?
bit.ly/42nXXLw
@marshalj23.bsky.social unpacks the turmoil hitting federal health agencies and what it means for researchers, clinical trials, and patient care. Who benefits from this chaos, and how can the medical community push back?
bit.ly/42nXXLw
Reposted
Targeted Therapy Options Sometimes Underutilized in Metastatic CRC. @marshalj23.bsky.social, discusses the sequencing of targeted therapy for refractory metastatic colorectal cancer.
www.targetedonc.com/view/targete...
www.targetedonc.com/view/targete...
Targeted Therapy Options Sometimes Underutilized in Metastatic CRC
John L. Marshall, MD, discusses the sequencing of targeted therapy for refractory metastatic colorectal cancer.
www.targetedonc.com
April 10, 2025 at 4:56 PM
Targeted Therapy Options Sometimes Underutilized in Metastatic CRC. @marshalj23.bsky.social, discusses the sequencing of targeted therapy for refractory metastatic colorectal cancer.
www.targetedonc.com/view/targete...
www.targetedonc.com/view/targete...
Reposted
The Role of ctDNA in CRC. cancernetwork.com/view/the-rol... via @marshalj23.bsky.social @marklewismd.bsky.social
The Role of ctDNA in CRC
Panelists discuss how circulating tumor DNA (ctDNA) serves as a promising biomarker for early detection, treatment monitoring, and recurrence surveillance in patients with colorectal cancer (CRC).
cancernetwork.com
April 1, 2025 at 4:53 PM
The Role of ctDNA in CRC. cancernetwork.com/view/the-rol... via @marshalj23.bsky.social @marklewismd.bsky.social
Reposted
BESPOKE: Study Design, Efficacy End Points, and Methods. cancernetwork.com/view/bespoke... via @marshalj23.bsky.social @marklewismd.bsky.social
BESPOKE: Study Design, Efficacy End Points and Methods
Panelists discuss how the BESPOKE study’s innovative design, carefully selected efficacy end points, and rigorous methodological approach aim to evaluate personalized therapeutic interventions with un...
cancernetwork.com
April 1, 2025 at 4:54 PM
BESPOKE: Study Design, Efficacy End Points, and Methods. cancernetwork.com/view/bespoke... via @marshalj23.bsky.social @marklewismd.bsky.social
Reposted
John L. Marshall, MD, discusses the impact of the SUNLIGHT trial in patients with refractory metastatic colorectal cancer. @marshalj23.bsky.social @georgetownlombardi.bsky.social
www.targetedonc.com/view/sunligh...
www.targetedonc.com/view/sunligh...
SUNLIGHT Findings Emphasize Role of VEGF Inhibition in Refractory CRC
John L. Marshall, MD, discusses the impact of the SUNLIGHT trial in patients with refractory metastatic colorectal cancer.
www.targetedonc.com
March 27, 2025 at 5:08 PM
John L. Marshall, MD, discusses the impact of the SUNLIGHT trial in patients with refractory metastatic colorectal cancer. @marshalj23.bsky.social @georgetownlombardi.bsky.social
www.targetedonc.com/view/sunligh...
www.targetedonc.com/view/sunligh...
Reposted
The Ruesch team was thrilled to participate in this year’s #ScopeItOut and to support the work of the Colorectal Cancer Alliance in raising awareness about #ColorectalCancer.
March 23, 2025 at 6:11 PM
The Ruesch team was thrilled to participate in this year’s #ScopeItOut and to support the work of the Colorectal Cancer Alliance in raising awareness about #ColorectalCancer.
Reposted
“Pancreatic cancer has been the graveyard for drug discovery,” said Benjamin Weinberg, MD, a gastrointestinal medical oncologist at @georgetownlombardi.bsky.social.
Researchers believe that could change with newer therapies, particularly those that target KRAS.
www.wsj.com/health/healt...
Researchers believe that could change with newer therapies, particularly those that target KRAS.
www.wsj.com/health/healt...
New Treatments Give Hope to Patients With One of the Deadliest Cancers
Half of all pancreatic-cancer patients live less than a year after diagnosis. But researchers say there is potential for change.
www.wsj.com
March 3, 2025 at 5:20 PM
“Pancreatic cancer has been the graveyard for drug discovery,” said Benjamin Weinberg, MD, a gastrointestinal medical oncologist at @georgetownlombardi.bsky.social.
Researchers believe that could change with newer therapies, particularly those that target KRAS.
www.wsj.com/health/healt...
Researchers believe that could change with newer therapies, particularly those that target KRAS.
www.wsj.com/health/healt...
Reposted
🎉 Subscribe to #OncologyUnscripted for:
✨ Groundbreaking science & industry updates
✨ Expert interviews reshaping clinical practice
✨ A unique blend of facts, fun, & insight you won’t find anywhere else
👉 Subscribe today bit.ly/41vFVWW
@clinicalcaresol.bsky.social
✨ Groundbreaking science & industry updates
✨ Expert interviews reshaping clinical practice
✨ A unique blend of facts, fun, & insight you won’t find anywhere else
👉 Subscribe today bit.ly/41vFVWW
@clinicalcaresol.bsky.social
March 6, 2025 at 4:23 PM
🎉 Subscribe to #OncologyUnscripted for:
✨ Groundbreaking science & industry updates
✨ Expert interviews reshaping clinical practice
✨ A unique blend of facts, fun, & insight you won’t find anywhere else
👉 Subscribe today bit.ly/41vFVWW
@clinicalcaresol.bsky.social
✨ Groundbreaking science & industry updates
✨ Expert interviews reshaping clinical practice
✨ A unique blend of facts, fun, & insight you won’t find anywhere else
👉 Subscribe today bit.ly/41vFVWW
@clinicalcaresol.bsky.social
Reposted
View this week's tailored GI Cancer publication output via bit.ly/4hoxqmx. What research was particularly interesting to you this week? Sign up today to have this weekly list delivered to your inbox: bit.ly/RueschWeeklyPub.
March 12, 2025 at 5:09 PM
View this week's tailored GI Cancer publication output via bit.ly/4hoxqmx. What research was particularly interesting to you this week? Sign up today to have this weekly list delivered to your inbox: bit.ly/RueschWeeklyPub.
Reposted
We were excited to join @fightcrc.bsky.social on the National Mall this evening to raise awareness about colorectal cancer at the United in Blue Rally. @georgetownlombardi.bsky.social #ColorectalCancerAwarenessMonth.
March 11, 2025 at 1:29 AM
We were excited to join @fightcrc.bsky.social on the National Mall this evening to raise awareness about colorectal cancer at the United in Blue Rally. @georgetownlombardi.bsky.social #ColorectalCancerAwarenessMonth.
Reposted
.@marshalj23.bsky.social reflects on the emotional toll of ongoing uncertainty in healthcare, particularly the impact on both providers and patients in the latest episode of #OncologyUnscripted. @clinicalcaresol.bsky.social bit.ly/3DxloJF
From Science to Survival: Cancer Research in Crisis
Dr Marshall highlights practice-changing research at ASCO GI, and discusses the turmoil caused by the new presidential administration’s abrupt policy changes.
bit.ly
March 7, 2025 at 6:02 PM
.@marshalj23.bsky.social reflects on the emotional toll of ongoing uncertainty in healthcare, particularly the impact on both providers and patients in the latest episode of #OncologyUnscripted. @clinicalcaresol.bsky.social bit.ly/3DxloJF
Reposted
'Prof Rahul Roychoudhuri, from the University of Cambridge, said: "What we've discovered is that aspirin might work, surprisingly, by unleashing the power of the immune system to recognize and kill metastasizing cancer cells."'
bbc.com/news/article...
bbc.com/news/article...
Aspirin: Scientists crack how painkiller might stop cancers from spreading
The cheap painkiller seems to help the immune system detect and destroy cancers.
bbc.com
March 6, 2025 at 1:51 AM
'Prof Rahul Roychoudhuri, from the University of Cambridge, said: "What we've discovered is that aspirin might work, surprisingly, by unleashing the power of the immune system to recognize and kill metastasizing cancer cells."'
bbc.com/news/article...
bbc.com/news/article...
Reposted
"It's essential that we all do our part to increase awareness of colonoscopy guidelines and alternatives, so individuals can make informed decisions about their health and potentially save their lives," added Priyanka Kanth, MD @medstarhealth.bsky.social.
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
MedStar Health Finds 79% of People Polled are Unaware of when to get a Colonoscopy
/PRNewswire/ -- A national survey conducted by MedStar Health to gauge the public's knowledge of screening guidelines for colorectal cancer, revealed 79% of...
www.prnewswire.com
March 3, 2025 at 6:39 PM
"It's essential that we all do our part to increase awareness of colonoscopy guidelines and alternatives, so individuals can make informed decisions about their health and potentially save their lives," added Priyanka Kanth, MD @medstarhealth.bsky.social.
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
Reposted
Dr Marshall highlights practice-changing research at ASCO GI (#GI25) and discusses the turmoil caused by the new presidential administration’s abrupt policy changes, which have disrupted federal health agencies, including the NIH and NCI. clinicalcaresolutions.net/activities/o...
From Science to Survival: Cancer Research in Crisis
Dr Marshall highlights practice-changing research at ASCO GI, and discusses the turmoil caused by the new presidential administration’s abrupt policy changes.
clinicalcaresolutions.net
February 18, 2025 at 2:23 AM
Dr Marshall highlights practice-changing research at ASCO GI (#GI25) and discusses the turmoil caused by the new presidential administration’s abrupt policy changes, which have disrupted federal health agencies, including the NIH and NCI. clinicalcaresolutions.net/activities/o...